Section 1: Overview and per
formance
11
Job No:
Proof Event:
Black Line Level:
4
Park Communications Ltd Alpine Way London E6 6LA
Customer:
Project Title:
Greater Europe Annual Rpt 2022
T:
0207 055 6500
F:
020 7055 6600
streams where business fundamentals
remain intact but share prices were, in
our view
, punished disproportionately
as interest rates rose. Thirdly
, a
smaller group of companies where
our asses
sment of the business
fundamentals was incorrect.
has since inception invested a portion
of its assets in Emerging European
significant part of this. This allocation
has in the past offered access to fast
growing markets at low valuations and
hence a differentiated source of capital
across all portfolios. As of 31 Januar
y
2022, the Company held 6.1% of its
net assets
there likely remains some intrinsic
value in these businesses, it is difficult
to see how this could be realised.
of companies, we found that the
negative share price returns were
driven by a change in the valuation
multiple ascribed to future profits
those profits will fail to materialise.
On the contrar
y
, the operational
per
formance of these busines
ses
remains strong, meeting or surpassing
cases we believe their competitive
positions are strengthening rather than
weakening. Thus, in our view share
prices have become disconnected from
fundamentals.
Lonza
share price having fallen by close to
in the year to date. The Swiss
company is a global leader in contract
manufacturing of high-end biological
drugs, as well as in fast growing and
emerging areas such as cell and gene
therapy
.
barriers to entry are wide
ranging and include manufacturing
and customer relationships with
manufacturers written into the drug
filings with regulators.
Lonza
’
s biologics business, which is
the highest margin part of the group,
to remain the growth engine at mid-
any incremental capacity they build
earns returns on invested capital of
close to 30% in our estimation. Lonza
’
s
global production capacity is sold out
only giving the company real pricing
power but also provides strong visibility
on its earnings trajector
y overall.
disappointing over the past year
, we
believe that the company’s potential to
outgrow the market over time remains
highly promising.
Adyen
, down over 40% over the last
year
, suffered a sell-off in line with
other tech names, which investors sold
with the rise of interest rates globally
.
the market is ignoring the long-term
class payment platform has taken the
lucrative payment processing industry
by storm. Adyen smoothly integrates
the full payments stack – gateway
, risk
management, processing, is
suing,
acquiring and settlement – on a single
platform and does that via multiple sales
channels (online, mobile and offline
channels) and via different currencies.
is straightfor
ward to onboard and
with its unified technology platform it
provides a cost and product capability
of the world’
s largest merchants use
Adyen. The vast majority of revenues
currently come from North America
and Europe, but we see potential for
geographical as well as mid-market
company recently reported 60% volume
growth, with revenues and profits also
seeing healthy improvements year-
on-year
. Some 80% of their revenue
clients and alongside this they have
acquired new high-quality clients which
themselves are growing faster than the
investment in
NetCompany
is an
fundamentals deteriorated and is
love’ with a stock. A key element of our
process is the constant reas
sessment
to gain deeper and deeper insights
and being prepared to change our
asses
sment should the fundamentals
require us to do so. NetCompany
, once
one of the Company’s high conviction
ideas, saw a significant change
after the company announced the
attraction to the company was based
on the entrepreneurial founder-led
culture and positioning in specific
Netherlands. The acquisition brought a
Europe and we felt NetCompany would
have difficultly integrating this new
business due to its size and operational
compared to 20% for NetCompany
and was operating at much lower
they had done in the past, we took the
view management would struggle to
its size. After initially reducing our
evidence of deteriorating operational
per
formance came through.
More positive to see are some of our
high conviction names that per
formed
a position in diabetes specialist
Novo
Nordisk
which was the top per
former
shares since 2017 and have grown
with the company over the years.
Novo Nordisk is one of two dominant
players in the global diabetes market,
to the nascent obesity drug market,
which in combination leaves this
business in a sweet spot with attractive
by the continued launch of Ozempic
should also be a steady flow of pipeline
readouts over the coming years (e.g.